U.S. Machinery Stock News

Quarterly miss, integration costs and deflation in focus Performance Food Group (PFGC) recently reported quarterly results where profit fell short of market expectations as Cheney Brothers integration costs and deflation in categories like cheese and poultry pressured margins, even as revenue continued to grow. Management reaffirmed revenue guidance for the upcoming quarter and maintained a positive longer term growth outlook. Analysts noted that higher operating expenses and acquisition...

Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda. These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market. Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...

If you are looking at Plains All American Pipeline and wondering whether the current price reflects its true worth, this article will help you frame that value question clearly. The stock last closed at US$20.15, with returns of 3.9% over 7 days, 5.7% over 30 days, 10.7% year to date, 11.0% over 1 year and a very large gain over 5 years that points to a big shift in how the market has treated the company over time. Recent coverage around Plains All American Pipeline has focused on its role...

Roku’s FY 2025 results reset the profit story Roku (ROKU) closed out FY 2025 with Q4 revenue of about US$1.4 billion and basic EPS of US$0.54, capping a year in which trailing twelve month revenue reached roughly US$4.7 billion and EPS landed at US$0.60. The company has seen quarterly revenue move from US$1.20 billion in Q4 2024 to US$1.39 billion in Q4 2025, while basic EPS shifted from a loss of US$0.24 to a profit of US$0.54. This gives investors a clearer view of how margins are now...

Cincinnati Financial Corporation recently reported fourth-quarter 2025 results, with revenue rising to US$3,091 million and net income to US$676 million, while basic earnings per share from continuing operations increased to US$4.34 from US$2.59 a year earlier. Beyond the headline beats, the insurer renewed key reinsurance treaties on improved terms and achieved underwriting profit despite experiencing the largest catastrophe loss in its history, underscoring the resilience of its business...

Leidos Holdings (NYSE:LDOS) is accelerating migrations of Defense Agencies to DODNet as part of the multi billion dollar Defense Enclave Services program. The company secured a federal contract to deliver integrated AI and Zero Trust security solutions for critical defense networks. Leidos announced new partnerships with RegScale and Trustible to automate cybersecurity compliance, continuous monitoring, and AI risk management for federal agencies. For investors watching defense IT...

Setting the scene on CVRx's latest results CVRx (CVRX) has reported third quarter FY 2025 revenue of US$14.7 million with a basic EPS loss of US$0.49, alongside trailing twelve month revenue of US$56.0 million and a basic EPS loss of US$2.02, giving investors a clear view of a company still in investment mode. The company has seen quarterly revenue move from US$11.8 million in Q2 2024 to US$14.7 million in Q3 2025. Quarterly basic EPS losses have ranged between US$0.43 and US$0.65 over the...

Are you wondering if NewMarket's current share price reflects its real worth, or if the recent moves have opened up a mispricing you could potentially take advantage of? The stock last closed at US$592.80, after an 18.1% decline over the past week and a 16.4% decline over the past month. This comes even though the 1 year, 3 year and 5 year returns sit at 11.1%, 82.1% and 67.3% respectively. Recent attention on NewMarket has focused on its role in the materials sector and how investors are...

Rivian Automotive (RIVN) just closed out FY 2025 with fourth quarter revenue of US$1.3 billion, a basic EPS loss of US$0.66, and net income loss of US$811 million, setting the tone for how investors will read the full year. Over the past six quarters, revenue has moved between US$874 million in Q3 2024 and US$1.7 billion in Q4 2024, while quarterly basic EPS has ranged from a loss of US$0.48 in Q1 2025 to a loss of US$1.08 in Q3 2024. This highlights a business that is scaling the top line...

If you are wondering whether MillerKnoll at around US$21.78 still offers value or if the easy gains are gone, this article will explain what the current price reflects in more detail. The stock has shown a mixed pattern, with a 13.2% return over the last 30 days and 19.3% year to date, but a 3.4% decline over the past week and a 32.0% decline over five years that some investors may still have in mind. Recent coverage has focused on how MillerKnoll fits into the commercial services and office...

How Fortune Brands Innovations' FY 2025 Numbers Stack Up Against the Story Fortune Brands Innovations (FBIN) just closed out FY 2025 with Q4 revenue of US$1,077.5 million and basic EPS of US$0.63, alongside net income of US$76.4 million, putting fresh numbers on the table for investors watching the story play out. The company has seen quarterly revenue range from US$1,033.1 million to US$1,203.3 million over the year, while basic EPS moved between US$0.42 and US$0.83. This gives a clearer...

Federal Realty Investment Trust posts mixed FY 2025 finish as one off item weighs on FFO Federal Realty Investment Trust (FRT) has wrapped up FY 2025 with Q4 revenue of US$334.4 million, Basic EPS of US$1.50 and Funds From Operations of a US$465.1 million loss, while trailing twelve month revenue came in at about US$1.3 billion and Basic EPS at US$4.69. Over recent periods, revenue has moved from US$312.8 million in Q4 2024 to US$334.4 million in Q4 2025, while Basic EPS has shifted from...

CareTrust REIT (CTRE) FY 2025 earnings snapshot CareTrust REIT (CTRE) has just wrapped up FY 2025 with fourth quarter revenue of US$134.9 million and basic EPS of US$0.50, rounding out a trailing twelve month revenue line of US$476.4 million and EPS of US$1.57. Over the past few reported periods, revenue has moved from US$86.9 million in Q4 2024 to US$134.9 million in Q4 2025, while quarterly basic EPS shifted from US$0.29 to US$0.50. The trailing net profit margin was reported at 67.3%,...

Lincoln National’s FY 2025 Earnings Snapshot Lincoln National (LNC) has just put fresh numbers on the table, with Q3 FY 2025 revenue of US$4.6 billion and basic EPS of US$2.15 setting the tone for its latest update. The company has seen quarterly revenue move from US$4.2 billion in Q3 FY 2024 to US$4.6 billion in Q3 FY 2025, while basic EPS has swung from a loss of US$3.29 to a profit of US$2.15 over the same period. This highlights how reported earnings have shifted across the past year...

Toast FY 2025 earnings snapshot Toast (TOST) reported first half FY 2025 revenue of US$2.9b with basic EPS of US$0.24, setting the tone for a year where profitability is firmly in focus. The company has seen revenue move from US$2.3b in the first half of 2024 to US$2.6b in the second half and then to US$2.9b in the first half of 2025. Over the same periods, basic EPS shifted from a loss of US$0.13 in early 2024 to US$0.16 and then US$0.24. With trailing net margins now higher than a year ago...

If you are wondering whether Science Applications International is starting to look interesting at current levels, this article will walk through what that price actually implies for its underlying value. The stock closed at US$86.61, with returns of an 11.9% decline over the past 7 days, a 19.9% decline over 30 days, a 14.4% decline year to date and a 13.0% decline over 1 year, as well as a roughly flat 0.1% gain over 5 years, which may have shifted how investors see its risk and potential...

Immunic (IMUX) has been in focus after a busy stretch, with board and leadership changes, fresh clinical data in multiple sclerosis, and a large private placement that brought in new and existing institutional investors. See our latest analysis for Immunic. The recent CEO transition plan, fresh MS data and the US$200.0m private placement appear to have coincided with sharp short term momentum, with a 7 day share price return of 47.18% and year to date share price return of 56.52%. This is set...

Columbia Financial, NasdaqGS:CLBK, has announced an agreement to acquire Northfield in a significant merger deal. The transaction is expected to combine two established regional banking franchises and materially change Columbia Financial's business profile. Investors are watching the deal for its potential impact on Columbia Financial's operations, balance sheet mix, and market reach. For shareholders, the news arrives with Columbia Financial shares at $18.41 and a mixed return profile. The...

Pacific Biosciences of California (PACB) just wrapped up FY 2025 with Q4 revenue of about US$44.6 million and a basic EPS loss of US$0.13, alongside a full year trailing revenue base of roughly US$160.0 million and a trailing basic EPS loss of US$1.82. Over recent quarters, the company has seen revenue move from US$39.2 million in Q4 2024 to US$44.6 million in Q4 2025. Quarterly basic EPS has shifted from a small profit of US$0.01 in Q4 2024 to losses between US$0.13 and US$1.44 across FY...

McGraw Hill (NYSE:MH) has appointed Philip Moyer as President and CEO, succeeding Simon Allen. The company is accelerating its push into AI powered education tools, gaining market share in higher education. McGraw Hill has been recognized as a leading user of AI in education and is rolling out new AI platforms with a focus on STEM. For investors watching NYSE:MH, the leadership transition comes as the company leans further into digital and AI centered offerings. The stock last closed at...

In early February 2026, Fluence Energy reported past first-quarter results showing revenue rising to US$475.23 million from US$186.79 million a year earlier, while net loss widened to US$45.07 million and loss per share increased to US$0.34. The company also reaffirmed its full-year 2026 revenue guidance of about US$3.20 billion to US$3.60 billion, underpinned by a fully covered backlog and over US$750 million in new orders, even as project cost overruns pressured margins. We’ll now...

If you are wondering whether ON Semiconductor is priced attractively right now, it helps to step back and look at how the current share price lines up with different valuation checks. The stock last closed at US$72.21, with returns of 10.8% over 7 days, 19.2% over 30 days, 27.4% year to date, 39.3% over 1 year, an 11.8% decline over 3 years, and 72.5% over 5 years. Recent price action has been shaped by ongoing investor interest in semiconductor names and how they might fit into themes such...

If you are trying to figure out whether HCI Group at around US$157.96 is still good value or already priced for perfection, you are in the right place. The stock has seen mixed returns, with a 3.3% decline over the last 7 days, a 10.5% decline over the last 30 days, a 14.1% decline year to date, a 34.6% gain over the last year and a very large 3 year return of 215.5% alongside a 192.5% return over 5 years. Recent price moves often tie back to changing views on insurance risk, regulatory...

10x Genomics FY 2025 earnings snapshot 10x Genomics (TXG) closed FY 2025 with Q4 revenue of US$166.0 million and a basic EPS loss of US$0.13, alongside trailing twelve month revenue of US$642.8 million and a TTM EPS loss of US$0.35 that keeps the focus squarely on the income statement. Over recent quarters the company has seen revenue range between US$149.0 million and US$172.9 million per quarter, with basic EPS swinging from a profit of US$0.28 in Q2 2025 to losses of US$0.28 in Q1, US$0.22...